Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine

被引：0
|
作者：
Mechtler, Laszlo [1 ]
Saikali, Nicolas [1 ]
McVige, Jennifer [1 ]
Hughes, Olivia [2 ]
Traut, Alexandra [3 ]
Adams, Aubrey [3 ]
机构：
[1] DENT Neurol Inst, Amherst, NY 14226 USA
[2] ICON Plc, Boston, MA USA
[3] AbbVie, Irvine, CA USA
来源：
TOXICON | 2022年 / 214卷
关键词：
Calcitonin gene-related peptide; Concomitant treatment; Migraine prevention; OnabotulinumtoxinA; Real-world; Safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S39 / S40
页数：2
相关论文
共 50 条
  • [1] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. HEADACHE, 2021, 61 : 176 - 177
  • [2] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 48 - 49
  • [3] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    [J]. FRONTIERS IN NEUROLOGY, 2022, 12
  • [4] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 74 - 74
  • [5] REAL-WORLD EVIDENCE FOR CONTROL OF PATIENTS WITH CHRONIC MIGRAINE WHO RECEIVED CGRP MONOCLONAL ANTIBODY THERAPY ADDED TO ONABOTULINUMTOXINA TREATMENT
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Adams, Aubrey Manack
    [J]. CEPHALALGIA, 2020, 40 : 96 - 97
  • [6] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Andrew M. Blumenfeld
    Benjamin M. Frishberg
    Jack D. Schim
    Ashley Iannone
    Gary Schneider
    Larisa Yedigarova
    Aubrey Manack Adams
    [J]. Pain and Therapy, 2021, 10 : 809 - 826
  • [7] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Manack Adams, Aubrey
    [J]. PAIN AND THERAPY, 2021, 10 (02) : 809 - 826
  • [8] Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Yedigarova, Larisa
    Adams, Aubrey Manack
    [J]. NEUROLOGY, 2021, 96 (15)
  • [9] Real-world evidence for chronic migraine control in patients receiving treatment with CGRP mAbs and onabotulinumtoxinA
    Blumenfeld, A.
    Frishberg, B.
    Schim, J.
    Hughes, O.
    Sommer, K.
    Adams, A. Manack
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 152 - 153
  • [10] Efficacy and Tolerability of CGRP Monoclonal Antibody Medications in Patients With Chronic Migraine Undergoing Treatment With OnabotulinumtoxinA
    Cohen, F.
    Armand, C. E.
    Vollbracht, S. E.
    [J]. HEADACHE, 2020, 60 : 13 - 13
12345